RAY1225 is named as a drug or biological intervention in 5 clinical trials in our China trial register, 2 of which are recruiting. The lead sponsor is Guangdong Raynovent Biotech Co., Ltd. Registered phases: Phase 3, Phase 2 and Phase 1. Conditions studied include Obesity; T2DM.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT06893016 | Evaluation of RAY1225 in Adult Participants Who Have Obesity or Are Overweight (ClinicalTrials.gov ↗) Obesity |
Phase 3 | Recruiting |
| NCT06254261 | A Study of RAY1225 in Participants With Obesity (ClinicalTrials.gov ↗) Obesity |
Phase 2 | Recruiting |
| NCT07139535 | A Study of RAY1225 in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone (ClinicalTrials.gov ↗) T2DM |
Phase 3 | Not yet open |
| NCT07139548 | A Study of RAY1225 Versus Semaglutide as Add-on Therapy to Oral Antidiabetic Drugs in Participants With Type 2 Diabetes (ClinicalTrials.gov ↗) T2DM |
Phase 3 | Not yet open |
| NCT07362030 | Drug-durg Interaction of RAY1225 With Warfarin, Atorvastatin, Metformin and Digoxin (ClinicalTrials.gov ↗) Obesity |
Phase 1 | Active, closed |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Obesity | 3 |
| T2DM | 2 |
| Lead sponsor | Trials |
|---|---|
| Guangdong Raynovent Biotech Co., Ltd | 5 |
| Register | RAY1225 trials |
|---|---|
| Clinical trials in China | 5 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how RAY1225 works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists RAY1225 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.